Plain-English translation of NCT06904911 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing tenecteplase, a clot-dissolving medication, to see if it can improve blood flow to the smallest blood vessels in the brain after emergency stroke treatment. Patients who have a large blockage in a major brain artery are treated with a procedure to remove the clot. After that procedure succeeds, researchers will give the medication directly into the affected artery to see if it helps restore better circulation to damaged brain tissue.
After emergency clot removal in stroke patients, blood flow to the tiny vessels in the brain tissue may still be inadequate, which can limit recovery. This trial is testing whether adding this medication could improve that small-vessel blood flow and potentially reduce brain damage.
You likely qualify if…
You likely don't qualify if…
After you undergo the emergency clot-removal procedure, doctors will perform special X-ray imaging to measure blood flow in the smallest vessels of your brain. Then, if you qualify, you will receive a single dose of the medication delivered directly into your brain artery through a catheter over about 5 minutes. Doctors will repeat the imaging to see if blood flow improves. You will have follow-up imaging at 24 hours and 72 hours after treatment, and your neurological recovery will be assessed at the hospital and again at 90 days.
AI-generated summary from trial data · Jul 22, 2026 · Not medical advice
United States